| MeSH term | MeSH ID | Detail |
|---|---|---|
| Pancreatic Neoplasms | D010190 | 77 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
| Arteriosclerosis | D001161 | 86 associated lipids |
Total
3
Norethindrone
Norethindrone is a lipid of Sterol Lipids (ST) class. Norethindrone is associated with abnormalities such as Endometriosis, site unspecified, Wiskott-Aldrich Syndrome and Estrogenic effect. The involved functions are known as Hemorrhage, Phosphorylation, Apoptosis, DNA Repair and Cell Cycle. Norethindrone often locates in Blood, Back, Body tissue, Nucleolar and Human tissue. The associated genes with Norethindrone are MMP gene, NR3C1 gene and Genes, Reporter. The related lipids are Steroids, 4,17 beta-dihydroxy-4-androstene-3-one, 4-estren-3,17-diol and Estranes.
Cross Reference
Introduction
To understand associated biological information of Norethindrone, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with Norethindrone?
Norethindrone is suspected in Endometriosis, site unspecified, Estrogenic effect and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with Norethindrone
PubChem Associated disorders and diseases
What pathways are associated with Norethindrone
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with Norethindrone?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with Norethindrone?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with Norethindrone?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with Norethindrone?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with Norethindrone?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with Norethindrone
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Oosterbaan HP et al. | The effects of continuous combined transdermal oestrogen-progestogen treatment on bleeding patterns and the endometrium in postmenopausal women. | 1995 | Maturitas | pmid:7616870 |
| Cagnacci A et al. | A comparison of the central effects of different progestins used in hormone replacement therapy. | 2004 | Maturitas | pmid:15283939 |
| Lazar F et al. | Carotid and uterine vascular resistance in short-term hormone replacement therapy postmenopausal users. | 2004 | Maturitas | pmid:15283941 |
| Norman-Taylor JQ et al. | Hormone replacement therapy by the transdermal administration of oestradiol and norethisterone. | 1994 | Maturitas | pmid:8015505 |
| Klehr-Bathmann I and Kuhl H | Formation of ethinylestradiol in postmenopausal women during continuous treatment with a combination of estradiol, estriol and norethisterone acetate. | 1995 | Maturitas | pmid:7616874 |
| Kaiser R | Duration of the climacteric syndrome in women treated by hormonal substitution and in controls. | 1984 | Maturitas | pmid:6727694 |
| Høvik P et al. | Comparison of continuous and sequential oestrogen-progestogen treatment in women with climacteric symptoms. | 1989 | Maturitas | pmid:2498620 |
| Campagnoli C et al. | Androgenic progestogens oppose the decrease of insulin-like growth factor I serum level induced by conjugated oestrogens in postmenopausal women. Preliminary report. | 1994 | Maturitas | pmid:7935029 |
| Nordin BE et al. | A placebo-controlled trial of ethinyl oestradiol and norethisterone in climacteric women. | 1980 | Maturitas | pmid:7003315 |
| Cornu C et al. | Postmenopause hormone treatment in women with NIDDM or impaired glucose tolerance: the MEDIA randomized clinical trial. | 2000 | Maturitas | pmid:11137328 |
| Lundström E et al. | Digitized assessment of mammographic breast density--effects of continuous combined hormone therapy, tibolone and black cohosh compared to placebo. | 2011 | Maturitas | pmid:21958943 |
| Mueck AO et al. | Impact of hormone replacement therapy on endogenous estradiol metabolism in postmenopausal women. | 2002 | Maturitas | pmid:12385856 |
| Franke HR and Vermes I | Differential effects of progestogens on breast cancer cell lines. | 2003 | Maturitas | pmid:14670646 |
| Christodoulacos G et al. | Transvaginal sonographic monitoring of the uterine effects of raloxifene and a continuous combined replacement therapy in postmenopausal women. | 2002 | Maturitas | pmid:12020983 |
| Norris LA et al. | Haemostatic risk factors in healthy postmenopausal women taking hormone replacement therapy. | 2002 | Maturitas | pmid:12385861 |
| Brynhildsen J and Hammar M | Lipids and clotting factors during low dose transdermal estradiol/norethisterone use. | 2005 | Maturitas | pmid:15780536 |
| Volpe A et al. | Benefits and risks of different hormonal replacement therapies in post-menopausal women. | 1986 | Maturitas | pmid:3033444 |
| Bruhat M et al. | Effective bleeding control and symptom relief by lower dose regimens of continuous combined hormone replacement therapy: a randomized comparative dose-ranging study. | 2001 | Maturitas | pmid:11731187 |
| Eilertsen AL et al. | The effects of oral and transdermal hormone replacement therapy on C-reactive protein levels and other inflammatory markers in women with high risk of thrombosis. | 2005 | Maturitas | pmid:16186073 |
| Silfverstolpe G et al. | Lipid metabolic studies in oophorectomised women: effects on serum lipids and lipoproteins of three synthetic progestogens. | 1982 | Maturitas | pmid:6811837 |
| Sporrong T et al. | A novel statistical approach to analysis of bleeding patterns during continuous hormone replacement therapy. | 1989 | Maturitas | pmid:2593864 |
| Yilmazer M et al. | Hormone replacement therapy, C-reactive protein, and fibrinogen in healthy postmenopausal women. | 2003 | Maturitas | pmid:14625121 |
| Cengiz B et al. | Effect of hormone replacement therapy on serum levels of tumor markers in healthy postmenopausal women. | 2003 | Maturitas | pmid:14625127 |
| Haapasaari KM et al. | Systemic therapy with estrogen or estrogen with progestin has no effect on skin collagen in postmenopausal women. | 1997 | Maturitas | pmid:9255750 |
| Alfie J et al. | Hemodynamic effects of transdermal estradiol alone and combined with norethisterone acetate. | 1997 | Maturitas | pmid:9255751 |
| Nerbrand C et al. | Effects of a lipid lowering fibrate and hormone replacement therapy on serum lipids and lipoproteins in overweight postmenopausal women with elevated triglycerides. | 2002 | Maturitas | pmid:12020980 |
| Christiansen C et al. | Low-risk lipoprotein pattern in post-menopausal women on sequential oestrogen/progestogen treatment. | 1984 | Maturitas | pmid:6727693 |
| Christodoulakos G et al. | Serum androgen levels and insulin resistance in postmenopausal women: association with hormone therapy, tibolone and raloxifene. | 2005 | Maturitas | pmid:15780533 |
| Riis BJ et al. | Continuous oestrogen-progestogen treatment and bone metabolism in post-menopausal women. | 1988 | Maturitas | pmid:3041248 |
| Lambrinoudaki IV et al. | Circulating leptin and ghrelin are differentially influenced by estrogen/progestin therapy and raloxifene. | 2008 | Maturitas | pmid:18164562 |
| Christodoulakos GE et al. | The effect of low dose hormone therapy on mammographic breast density. | 2006 | Maturitas | pmid:16198519 |
| Modena MG et al. | New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits. | 2005 | Maturitas | pmid:15963666 |
| Staland B | Continuous treatment with natural oestrogens and progestogens. A method to avoid endometrial stimulation. | 1981 | Maturitas | pmid:7026979 |
| von Holst T et al. | Bleeding patterns in peri and postmenopausal women taking a continuous combined regimen of estradiol with norethisterone acetate or a conventional sequential regimen of conjugated equine estrogens with medrogestone. | 2002 | Maturitas | pmid:12468135 |
| Thunell L et al. | The effect of continuous combined HRT on glucose homeostasis and plasma lipids. A placebo-controlled study in postmenopausal women with type 2 diabetes. | 2006 | Maturitas | pmid:16198072 |
| Odmark IS et al. | Effects of continuous combined conjugated estrogen/medroxyprogesterone acetate and 17beta-estadiol/norethisterone acetate on lipids and lipoproteins. | 2004 | Maturitas | pmid:15172088 |
| Kwok S et al. | Effects of dydrogesterone and norethisterone, in combination with oestradiol, on lipoproteins and inflammatory markers in postmenopausal women. | 2006 | Maturitas | pmid:16139447 |
| Luotola H et al. | Effects of natural oestrogen/progestogen substitution therapy on carbohydrate and lipid metabolism in post-menopausal women. | 1986 | Maturitas | pmid:3537636 |
| Zhou J et al. | Medroxyprogesterone acetate-driven increase in breast cancer risk might be mediated via cross-talk with growth factors in the presence of progesterone receptor membrane component-1. | 2013 | Maturitas | pmid:23856385 |
| Riis BJ and Christiansen C | Post-menopausal bone loss: effects of oestrogens and progestogens. A review. | 1986 | Maturitas | pmid:3553863 |
| Oguz S et al. | The role of hormone replacement therapy in endometrial polyp formation. | 2005 | Maturitas | pmid:15734604 |
| al-Azzawi F et al. | Investigation of the bleeding patterns of postmenopausal women treated with Estrapak-50. | 1994 | Maturitas | pmid:8177092 |
| Posaci C et al. | Effects of HRT on serum levels of IGF-I in postmenopausal women. | 2001 | Maturitas | pmid:11684375 |
| Lübbert H and Nauert C | Continuous versus cyclical transdermal estrogen replacement therapy in postmenopausal women: influence on climacteric symptoms, body weight and bleeding pattern. | 1997 | Maturitas | pmid:9522319 |
| Eilertsen AL et al. | Conventional-dose hormone therapy (HT) and tibolone, but not low-dose HT and raloxifene, increase markers of activated coagulation. | 2006 | Maturitas | pmid:16713143 |
| Glusa E et al. | Mechanisms of relaxation of rat aorta in response to progesterone and synthetic progestins. | 1997 | Maturitas | pmid:9522326 |
| Tuppurainen M et al. | Effects of continuous combined hormone replacement therapy and clodronate on bone mineral density in osteoporotic postmenopausal women: a 5-year follow-up. | 2010 | Maturitas | pmid:20547017 |
| Paterson ME | A randomised, double-blind, cross-over study into the effect of sequential mestranol and norethisterone on climacteric symptoms and biochemical parameters. | 1982 | Maturitas | pmid:6750325 |
| Stadberg E et al. | 17 beta-estradiol and norethisterone acetate in low doses as continuous combined hormone replacement therapy. | 1996 | Maturitas | pmid:8861084 |
| Raudaskoski TH et al. | Serum lipids and lipoproteins in postmenopausal women receiving transdermal oestrogen in combination with a levonorgestrel-releasing intrauterine device. | 1995 | Maturitas | pmid:7666816 |
| Lindgren R et al. | Transdermal hormonal replacement therapy with transdermal progestin every second month. | 1995 | Maturitas | pmid:7666813 |
| Gambacciani M et al. | Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women. | 2008 | Maturitas | pmid:18063490 |
| Byrjalsen I et al. | Serum placental protein 14 in pre-menopausal and post-menopausal women--dependency on oestrogen/progestogen status. | 1990 | Maturitas | pmid:2255265 |
| Saarikoski S et al. | Sequential use of norethisterone and natural progesterone in pre-menopausal bleeding disorders. | 1990 | Maturitas | pmid:2255266 |
| Mattsson LA et al. | Evaluation of a continuous oestrogen-progestogen regimen for climacteric complaints. | 1982 | Maturitas | pmid:7121296 |
| Schindler AE et al. | Classification and pharmacology of progestins. | 2003 | Maturitas | pmid:14670641 |
| Jensen J et al. | Long-term and withdrawal effects of two different oestrogen-progestogen combinations on lipid and lipoprotein profiles in post-menopausal women. | 1989 | Maturitas | pmid:2547137 |
| Pata O et al. | The effects of hormone replacement therapy type on pulmonary functions in postmenopausal women. | 2003 | Maturitas | pmid:14585524 |
| Campagnoli C et al. | Positive effects on cardiovascular and breast metabolic markers of oral estradiol and dydrogesterone in comparison with transdermal estradiol and norethisterone acetate. | 2002 | Maturitas | pmid:12034517 |
| Hellberg D and Nilsson S | Comparison of a triphasic oestradiol/norethisterone acetate preparation with and without an oestriol component in the treatment of climacteric complaints. | 1984 | Maturitas | pmid:6429481 |
| Keller PJ et al. | A transdermal regimen for continuous combined hormone replacement therapy in the menopause. | 1992 | Maturitas | pmid:1465033 |
| Christodoulakos GE et al. | The effect of various regimens of hormone replacement therapy on mammographic breast density. | 2003 | Maturitas | pmid:12787969 |
| Fotherby K | Pharmacokinetics of progestational compounds. | 1986 | Maturitas | pmid:2943973 |
| Mehring W | [The effect of ovulation inhibitors on the vaginal picture and the portio epithelium]. | 1965 | Med Klin | pmid:5870226 |
| Norethindrone--the "minipill". | 1973 | Med Lett Drugs Ther | pmid:4712978 | |
| Norinyl 1+80 and Ortho-Novum 1/80. | 1969 | Med Lett Drugs Ther | pmid:5778361 | |
| Ortho-Novum 10/11--a new "bi-phasic" oral contraceptive. | 1982 | Med Lett Drugs Ther | pmid:7121396 | |
| Three new combination oral contraceptives: Seasonique, Loestrin 24 Fe, and Yaz. | 2006 | Med Lett Drugs Ther | pmid:17001297 | |
| Lachnit-Fixson U and Aydinlik S | [New cycle-stabilizing contraceptive agent (Ediwal)]. | 1976 | Med Monatsschr | pmid:979900 |
| Zaffaroni A | Systems for controlled drug delivery. | 1981 | Med Res Rev | pmid:7050567 |
| GOLDFARB AF et al. | OVULATION CONTROL. | 1963 | Med Sci | pmid:14081010 |
| DEHAEN P | THERAPEUTIC RESEARCH IN REVIEW. | 1964 | Med Sci | pmid:14143127 |
| Ranneberg KM and Holzmann H | [Herpes gestationis recurrence caused by synthetic gestagens]. | 1970 | Med Welt | pmid:4249079 |
| HEINEN G | [Oral contraception]. | 1962 | Med Welt | pmid:13953432 |
| GOLDZIEHER JW | NEWER DRUGS IN ORAL CONTRACEPTION. | 1964 | Med. Clin. North Am. | pmid:14149247 |
| Stoll BA | Therapy by progestational agents in advanced breast cancer. | 1966 | Med. J. Aust. | pmid:5906684 |
| CUNINGHAM K and LANG WR | Result of a blind clinical trial conducted on 50 cases of hormonal mastopathy. | 1962 | Med. J. Aust. | pmid:14024258 |
| Roxburgh DR and West MJ | The use of norethisterone to suppress menstruation in the intellectually severely retarded woman. | 1973 | Med. J. Aust. | pmid:4746398 |
| Kneale B and Evans J | Progestogen therapy for advanced carcinoma of the endometrium. | 1969 | Med. J. Aust. | pmid:5374044 |
| Fraser IS and Weisberg E | A comprehensive review of injectable contraception with special emphasis on depot medroxyprogesterone acetate. | 1981 | Med. J. Aust. | pmid:6453269 |
| MacLennan AH et al. | Continuous low-dose oestrogen and progestogen hormone replacement therapy: a randomised trial. | 1993 | Med. J. Aust. | pmid:8336583 |
| PLANT GH | PRODUCTION AND QUALITY CONTROL OF AN ORAL CONTRACEPTIVE. | 1965 | Med. J. Aust. | pmid:14265218 |
| BROWN MM | PREMENSTRUAL METATARSALGIA. | 1965 | Med. J. Aust. | pmid:14315259 |
| Wren BG | Minimal dose combined hormonal replacement therapy for menopausal women. | 1981 | Med. J. Aust. | pmid:7242418 |
| Gattanell PN et al. | Hepatocellular carcinoma in a young woman with prolonged exposure to oral contraceptives. | 1978 | Med. Pediatr. Oncol. | pmid:207962 |
| Czarnecka D et al. | The effect of hormone replacement therapy on endothelial function in postmenopausal women with hypertension. | 2004 | Med. Sci. Monit. | pmid:14737044 |
| Kyriakou A and Skordis N | Thalassaemia and aberrations of growth and puberty. | 2009 | Mediterr J Hematol Infect Dis | pmid:21415985 |
| Georgiev DB and Manassiev NA | Effect of long-term continuous combined hormone replacement therapy with estradiol valerate and either dienogest or norethisterone acetate on mammographic density in postmenopausal women. | 2002 Jul-Aug | Medscape Womens Health | pmid:12466733 |
| Brynhildsen J and Hammar M | Low dose transdermal estradiol/norethisterone acetate treatment over 2 years does not cause endometrial proliferation in postmenopausal women. | 2002 Mar-Apr | Menopause | pmid:11875333 |
| Liang Y et al. | Synthetic progestins induce growth and metastasis of BT-474 human breast cancer xenografts in nude mice. | 2010 Sep-Oct | Menopause | pmid:20461021 |
| Simon JA and Symons JP | Unscheduled bleeding during initiation of continuous combined hormone replacement therapy: a direct comparison of two combinations of norethindrone acetate and ethinyl estradiol to medroxyprogesterone acetate and conjugated equine estrogens. | 2001 Sep-Oct | Menopause | pmid:11528357 |
| Rolnick SJ et al. | Hormone use and patient concerns after the findings of the Women's Health Initiative. | 2005 Jul-Aug | Menopause | pmid:16037754 |
| Mueck AO et al. | Low-dose continuous combinations of hormone therapy and biochemical surrogate markers for vascular tone and inflammation: transdermal versus oral application. | 2007 Nov-Dec | Menopause | pmid:17595593 |
| Dören M et al. | Impact on uterine bleeding and endometrial thickness: tibolone compared with continuous combined estradiol and norethisterone acetate replacement therapy. | 1999 | Menopause | pmid:10614676 |
| Samsioe G et al. | Changes in lipid and lipoprotein profile in postmenopausal women receiving low-dose combinations of 17beta-estradiol and norethisterone acetate. | 2002 Sep-Oct | Menopause | pmid:12218722 |
| Walker RJ et al. | The effects of sequential combined oral 17beta-estradiol norethisterone acetate on insulin sensitivity and body composition in healthy postmenopausal women: a randomized single blind placebo-controlled study. | 2001 Jan-Feb | Menopause | pmid:11201511 |
| Seeger H et al. | Effect of medroxyprogesterone acetate and norethisterone on serum-stimulated and estradiol-inhibited proliferation of human coronary artery smooth muscle cells. | 2001 Jan-Feb | Menopause | pmid:11201515 |
| Ursic-Vrscaj M et al. | Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: the effect on survival. | 2001 Jan-Feb | Menopause | pmid:11201519 |
| Hemelaar M et al. | Hemostatic markers in healthy postmenopausal women during intranasal and oral hormone therapy: a randomized trial. | 2008 Mar-Apr | Menopause | pmid:17693902 |
| Kimmerle R et al. | Influence of continuous combined estradiol-norethisterone acetate preparations on insulin sensitivity in postmenopausal nondiabetic women. | 1999 | Menopause | pmid:10100178 |